Discovery, Biology and Risk of Inherited Variants in Breast Cancer

乳腺癌遗传变异的发现、生物学和风险

• 批准号: 8549150
• 负责人: Habibul Ahsan
• 金额: $ 230.98万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-15 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8549150
• 关键词: 3-Dimensional; Address; African American; Algorithms; Asians; Biological; Biological Assay; Biology; Breast; Breast Cancer Risk Factor; Chemoprevention; Clinical; Clinical assessments; Collaborations; Data; Data Analyses; Distant; Epithelial Cells; Family history of; Genes; Genetic Variation; Genie; High Risk Woman; In Vitro; Inherited; Intercistronic Region; Investigation; Link; Mammary Neoplasms; Maps; Measures; Modeling; Modification; Molecular Conformation; Morphogenesis; Normal tissue morphology; Phase; Phenotype; Primary Prevention; Prospective Studies; RNA; Resources; Risk; Risk Factors; Sample Size; Series; Stromal Cells; Tamoxifen; Testing; Transcript; Translations; Tumor Tissue; Variant; Woman; cancer risk; clinical decision-making; clinical practice; cohort; data modeling; evidence base; gain of function; gene discovery; gene function; gene interaction; genetic variant; genome wide association study; genome-wide; high risk; malignant breast neoplasm; non-genetic; protective effect; risk variant; tumorigenesis

DESCRIPTION (provided by applicant): We propose an integrated multiple-PI Project to systematically discover and replicate additional common genetic variants associated with breast cancer, assess their biological significance, and develop evidence based assessments of the clinical validity of prediction algorithms using these variants, and their suitability for translation into clinical practice. In sub-Project 1 we will combine the resources of (a) major GWAS for breast cancer amounting to >15,000 cases and (b) three pre-existing Consortia with over 48,000 additional cases to provide the large sample size needs necessary in the replication phase of GWAS. We will fine map the associated loci in collaboration with the major Consortia conducting GWAS for breast cancer in Asian and African-American women. In sub-Project 2 we will conduct a series of investigations to (a) assign a gene function to each replicated risk variant by measuring expression of 24,000 RNA transcripts in breast tumor tissue and normal tissue, from women for whom we also have an lllumina 540 GWAS available; by identifying networks of genes in which alterations of expression can be linked to specific germline risk variants; and by using Chromosomal Conformation Capture assays to examine whether associated intergenic regions fold physically in a way that brings them into contact with distant genie regions. We will also (b) examine whether loss or gain of function of the genes implicated in (a) in breast epithelial cells or stromal cells alter phenotypes in vitro in a 3-D model of breast morphogenesis and oncogenesis. In sub- Project 3, we will develop breast cancer prediction models that can be used to stratify women according to breast cancer risk. We will attempt to discover gene-gene interactions by reanalyzing the GWAS data, and we will systematically examine the genome-wide significant gene variants for effect modification by established breast cancer risk factors, using the largest set of prospective studies available. We will develop and refine risk models that incorporate both the germline risk factors and the established non-genetic risk factors, and also assess these in a cohort of women with higher familial risk of breast cancer (to specifically address the clinical needs of women at high risk due to a strong family history of breast cancer). Finally, we will analyze data from the major trials of primary prevention of breast cancer to address the question of whether the protective effect of tamoxifen is altered by risk status for our prediction models, data with a direct bearing on clinical decision-making with respect to chemoprevention for women at known high risk.

描述（由申请人提供）：我们提出了一个集成的多pi项目，系统地发现和复制与乳腺癌相关的其他常见遗传变异，评估其生物学意义，并基于证据评估使用这些变异的预测算法的临床有效性，以及它们转化为临床实践的适用性。在子项目1中，我们将结合(a)针对乳腺癌的主要GWAS的资源（总计1,500,000例）和(b)三个已有的超过48,000例的联盟的资源，以提供GWAS复制阶段所需的大量样本。我们将与开展亚洲和非裔美国妇女乳腺癌GWAS的主要协会合作，绘制相关基因座的精细图谱。在子项目2中，我们将进行一系列调查，以(a)通过测量乳腺肿瘤组织和正常组织中24,000个RNA转录本的表达，为每个复制的风险变异分配基因功能，这些女性也有lllumina 540 GWAS可用；通过识别表达改变与特定种系风险变异相关的基因网络；并通过使用染色体构象捕获测定来检查相关的基因间区域是否以一种使它们与遥远的基因区域接触的方式进行物理折叠。我们还将(b)在乳腺形态发生和肿瘤发生的三维模型中，研究(a)中乳腺上皮细胞或基质细胞中涉及的基因功能的丧失或获得是否会改变体外表型。在子项目3中，我们将开发乳腺癌预测模型，可用于根据乳腺癌风险对妇女进行分层。我们将尝试通过重新分析GWAS数据来发现基因-基因之间的相互作用，我们将使用最大的前瞻性研究集，系统地检查全基因组范围内重要的基因变异，以确定乳腺癌危险因素的影响。我们将开发和完善风险模型，其中包括生殖系风险因素和已建立的非遗传风险因素，并在具有较高乳腺癌家族风险的女性队列中进行评估（专门针对具有强烈乳腺癌家族史的高风险女性的临床需求）。最后，我们将分析来自主要乳腺癌一级预防试验的数据，以解决他莫昔芬的保护作用是否会因我们的预测模型的风险状态而改变的问题，这些数据与已知高风险女性的化学预防的临床决策直接相关。